TY - JOUR
T1 - The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives
AU - Study Group of the European Competence Network on Mastocytosis (ECNM)
AU - Valent, Peter
AU - Oude Elberink, Joanna N.G.
AU - Gorska, Aleksandra
AU - Lange, Magdalena
AU - Zanotti, Roberta
AU - van Anrooij, Björn
AU - Bonifacio, Massimiliano
AU - Bonadonna, Patrizia
AU - Gleixner, Karoline V.
AU - Hadzijusufovic, Emir
AU - Perkins, Cecelia
AU - Hartmann, Karin
AU - Illerhaus, Anja
AU - Merante, Serena
AU - Elena, Chiara
AU - Shoumariyeh, Khalid
AU - von Bubnoff, Nikolas
AU - Parente, Roberta
AU - Triggiani, Massimo
AU - Schwaab, Juliana
AU - Jawhar, Mohamad
AU - Caroppo, Francesca
AU - Fortina, Anna Belloni
AU - Brockow, Knut
AU - David Fuchs, Fuchs
AU - Greul, Rosemarie
AU - Yavuz, Akif Selim
AU - Doubek, Michael
AU - Mattsson, Mattias
AU - Hagglund, Hans
AU - Panse, Jens
AU - Sabato, Vito
AU - Aberer, Elisabeth
AU - Al-Ali, Haifa Kathrin
AU - Morren, Marie Anne
AU - Varkonyi, Judit
AU - Zink, Alexander
AU - Niedoszytko, Marek
AU - Niederwieser, Dietger
AU - Malcovati, Luca
AU - Reiter, Andreas
AU - Kennedy, Vanessa
AU - Gotlib, Jason
AU - Lortholary, Olivier
AU - Hermine, Olivier
AU - Arock, Michel
AU - Kluin-Nelemans, Hanneke C.
AU - Sperr, Wolfgang R.
N1 - Publisher Copyright:
© 2019 American Academy of Allergy, Asthma & Immunology
PY - 2019/1
Y1 - 2019/1
N2 - Mastocytosis is a unique hematologic neoplasm with complex biology and pathology and a variable clinical course. The disease can essentially be divided into cutaneous mastocytosis (CM) and systemic mastocytosis (SM). In adults, SM is diagnosed in most cases and manifests as either indolent or advanced disease. Patients with advanced SM have an unfavorable prognosis with reduced survival. However, so far, little is known about the prevalence of various categories of SM and about prognostic factors. In an attempt to learn more about the behavior and evolution of various forms of CM and SM, the European Competence Network on Mastocytosis (ECNM) initiated a mastocytosis registry in 2012. In this article, the set up and start phase of this registry are described. Until 2018, more than 3000 patients from 12 countries and 25 centers have been enrolled. In a majority of all patients, robust follow-up data and relevant clinical end points are available. Using this data set, a series of registry projects have been launched, with the aim to validate previously identified diagnostic and prognostic variables and to identify new disease-related and patient-related parameters in various forms of mastocytosis. Moreover, the core data set of the registry will be useful to establish multiparametric scoring systems through which prognostication and individualized management of patients with mastocytosis should improve in the foreseeable future.
AB - Mastocytosis is a unique hematologic neoplasm with complex biology and pathology and a variable clinical course. The disease can essentially be divided into cutaneous mastocytosis (CM) and systemic mastocytosis (SM). In adults, SM is diagnosed in most cases and manifests as either indolent or advanced disease. Patients with advanced SM have an unfavorable prognosis with reduced survival. However, so far, little is known about the prevalence of various categories of SM and about prognostic factors. In an attempt to learn more about the behavior and evolution of various forms of CM and SM, the European Competence Network on Mastocytosis (ECNM) initiated a mastocytosis registry in 2012. In this article, the set up and start phase of this registry are described. Until 2018, more than 3000 patients from 12 countries and 25 centers have been enrolled. In a majority of all patients, robust follow-up data and relevant clinical end points are available. Using this data set, a series of registry projects have been launched, with the aim to validate previously identified diagnostic and prognostic variables and to identify new disease-related and patient-related parameters in various forms of mastocytosis. Moreover, the core data set of the registry will be useful to establish multiparametric scoring systems through which prognostication and individualized management of patients with mastocytosis should improve in the foreseeable future.
UR - http://www.scopus.com/inward/record.url?scp=85056241477&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2018.09.024
DO - 10.1016/j.jaip.2018.09.024
M3 - Scientific review articles
C2 - 30416055
AN - SCOPUS:85056241477
SN - 2213-2198
VL - 7
SP - 81
EP - 87
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 1
ER -